STOCK TITAN

Enlivex Announces Positive Interim DSMB Safety Review, Supporting Continued Enrollment in Phase IIb Knee Osteoarthritis Trial

(Very High)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Enlivex (ENLV) can continue enrollment as planned in its Phase IIb Allocetra knee osteoarthritis trial after an independent interim safety review. The Data and Safety Monitoring Board reviewed data from 85 patients who were randomly assigned and dosed. Enlivex's chief medical officer said the interim findings appeared consistent with the safety profile observed in the earlier Phase I/IIa trial.

The placebo-controlled trial (NCT07580716) plans to enroll approximately 182 patients in the United States, Denmark and Poland. It evaluates three injections into the joint in patients aged 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis. The trial measures changes from baseline in pain and physical function versus placebo at three and six months after treatment.

Loading...
Loading translation...

Positive

  • Minor point. Forward-looking: it has not happened yet and may not happen.Independent interim safety review of 85 randomized and dosed patients supports continued Phase IIb enrollment as planned
  • Minor pointInterim safety findings appeared consistent with the earlier Phase I/IIa safety profile, Enlivex's chief medical officer said

Negative

  • None.

Key Figures

Patients in interim review: 85 patients Planned enrollment: approximately 182 patients
Patients in interim review
85 patients
Randomized and dosed in the Phase IIb trial
Planned enrollment
approximately 182 patients
Phase IIb trial

Previous Clinical trial Reports

2 past events · Latest: Nov 02
Same Type 2 events
  1. Nov 02

    Phase IIa results

    24h Move
    -20.8%

    Phase IIa results reported no treatment-related serious adverse events and a favorable safety profile.

  2. Oct 28

    Phase IIb enrollment

    24h Move
    -3.3%

    Prior update reported 135 patients randomized in the same Phase IIb trial; 182 were planned.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

data and safety monitoring board, intra-articular
2 terms
data and safety monitoring board medical
"independent Data and Safety Monitoring Board (DSMB)"
An independent panel of experts that watches over a clinical trial to protect participants and ensure the data are reliable, acting like an impartial referee who can recommend pausing or stopping the study if safety problems or clear benefits emerge. Investors care because the board’s findings can change a drug or device’s timeline, cost, and odds of regulatory approval, directly affecting a company’s value and risk profile.
intra-articular medical
"3 intra-articular injections of Allocetra™"
An intra-articular treatment is one that is injected directly into a joint space, such as the knee or shoulder, to deliver medication or therapy right where the problem is. For investors, this matters because intra-articular delivery can improve effectiveness and reduce systemic side effects compared with pills or injections elsewhere in the body, affecting a drug’s clinical value, regulatory pathway, market appeal, and reimbursement prospects.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

Nes-Ziona, Israel, Nov. 18, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) ("Enlivex" or the "Company"), a quality longevity company powered by a prediction markets treasury, today announced that the independent Data and Safety Monitoring Board (DSMB) overseeing the Company's randomized, double-blind, placebo-controlled Phase IIb trial evaluating Allocetra™ in patients with primary age-related knee osteoarthritis has completed an interim safety review of data from 85 patients randomized and dosed in the trial. Following review of the data, the DSMB confirmed that the safety profile of Allocetra™ allows the Company to continue enrolling patients in the trial as planned.

“The outcome of this interim review, covering 85 patients randomized and dosed in the trial, appears consistent with the favorable safety profile observed in our Phase I/IIa trial,” said Einat Galamidi, Chief Medical Officer of Enlivex. “We are pleased with the DSMB’s decision that the trial will continue as planned and designed, and we remain focused on executing the Phase IIb trial and look forward to reporting topline data.”

About the Phase IIb Trial

The Phase IIb trial (NCT07580716), is a randomized, double-blind, placebo-controlled, global, multicenter, clinical trial which is designed to evaluate the efficacy and safety of 3 intra-articular injections of Allocetra™ in patients 64 and older with moderate-to-severe symptomatic primary knee osteoarthritis. The trial is planned to enroll approximately 182 patients from clinical centers in the United States, Denmark and Poland. Key efficacy endpoints include changes from baseline of pain and physical function compared with placebo, measured at three- and six-month periods following treatment. Additional endpoints include changes in quality-of-life measures, functional mobility assessments and one year follow-up.

About Knee Osteoarthritis

Osteoarthritis (OA) is one of the most prevalent and disabling diseases worldwide, affecting more than 32 million Americans today and projected to continue to grow substantially, with knee OA (KOA) being the most prevalent form. There are currently no approved disease-modifying therapies; treatment is largely limited to pain relief, intra-articular steroids, or surgery, and the burden increases sharply with age. By age 60, KOA affects roughly 30% of the population, and about half of KOA patients are 60 years of age or older. This demographic is expanding with global aging trends, underscoring the need for new, durable therapies.

About Enlivex

Enlivex is a quality longevity company powered by a prediction markets treasury. The Company is advancing Allocetra™, an advanced clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with a primary focus on age-related osteoarthritis. In addition to its clinical programs, Enlivex operates a prediction markets treasury strategy built around the Rain Protocol, the leading decentralized prediction markets infrastructure on Arbitrum. This dual strategy combines the development of quality longevity therapeutics with exposure to the emerging prediction markets ecosystem.

Forward-looking statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would," "could," "intends," "estimates," "suggests," "target," "has the potential to," "goal," and other words of similar meaning, including statements relating to the anticipated benefits of the Company's digital asset treasury strategy; the assets to be held by the Company; the expected future market, price, trading activity, and liquidity of the RAIN token; the impact of expanded exchange listings and increased token liquidity on market participation and accessibility; the potential effects of digital asset liquidity on the liquidity of the Company's ordinary shares; macroeconomic, political, and regulatory conditions surrounding digital assets; the Company's plans for value creation and strategic positioning; market size and growth opportunities; regulatory conditions; competitive position; technological and market trends; future financial condition and performance; expected clinical trial results; market opportunities for the results of current clinical studies and preclinical experiments; and the effectiveness of, and market opportunities for, ALLOCETRA™ programs.

Each forward-looking statement contained in this press release is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statement. Applicable risks and uncertainties include, among others, the risk that results from subgroup analyses and small patient populations, including those described in this press release, may not be replicated in larger trials, including the Company's ongoing Phase IIb trial; the risk that topline data may change following a more comprehensive review of the data; the risk that RMAT designation may not lead to a faster development or regulatory review process and does not increase the likelihood of approval; risks related to the timing, conduct and outcome of clinical trials and regulatory submissions; the risk of failure to realize the anticipated benefits of the Company's digital asset treasury strategy; changes in business, market, financial, political, and regulatory conditions; risks relating to the Company's operations and business, including the highly volatile nature of the price, trading volume, and liquidity of RAIN and other cryptocurrencies; risks associated with digital asset exchange listings, trading venues, and market infrastructure; the risk that the price and liquidity of the Company's ordinary shares may be correlated with the price or liquidity of the digital assets it holds; risks related to increased competition in the industries in which the Company operates; risks relating to significant legal, commercial, regulatory, and technical uncertainty regarding digital assets generally; risks relating to the treatment of crypto assets for U.S. and foreign tax purposes; and those risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. The forward-looking statements in this press release speak only as of the date of this document, and the Company undertakes no obligation to update or revise any of these statements, except as required by applicable law.

Enlivex contact
Shachar Shlosberger
CFO
Enlivex Ltd.
shachar@enlivex.com


FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did the interim safety review of Enlivex's Phase IIb Allocetra knee osteoarthritis trial find?

The independent monitoring board concluded that Allocetra's safety profile allowed enrollment to continue as planned. The review covered 85 patients who were randomized and dosed.

What outcomes is Enlivex measuring in its Phase IIb Allocetra knee osteoarthritis trial?

The trial measures changes in pain and physical function versus placebo from baseline to three and six months after treatment. It also assesses changes in quality of life and functional mobility and includes one year of follow-up.

Keep reading